Approximately 40% of people living with #atopicdermatitis consider their condition to be moderate-to-severe. This is more than just a number for Amgen 🧪🔬🧬 and @KyowaKirin_US, that's why we're committed to addressing unmet needs faced by the atopic dermatitis community.